Aurora Analytica Awarded Innovation Norway Start-up 2 Grant
We are thrilled to announce that Aurora Analytica has been awarded the prestigious Start-up 2 (Oppstart 2) grant from Innovation Norway. This marks another significant milestone in our journey, as we continue to advance the development of the Aurora Suite, our AI-driven platform designed to optimize clinical trial strategy and execution.
Innovation Norway
A Rigorous Process, A Resounding Endorsement
Receiving this grant is not just about financial support—it is a testament to the robust and comprehensive evaluation process that Innovation Norway applies when selecting high-potential startups for funding. The review process assesses both technological innovation and commercial viability, ensuring that only the most promising companies receive support.
Being awarded the Startup2 grant validates our vision and mission, reinforcing the confidence in our technology and its potential to revolutionize clinical trials. This recognition from Innovation Norway signals strong trust in our ability to bring innovative, impactful solutions to market.
Driving Innovation in Clinical Trial Optimization
At Aurora Analytica, our goal is to transform the way CROs, biotech and pharma companies design and optimize clinical trials. With the support of this grant, we will continue refining the Aurora Suite, leveraging AI-driven insights, advanced analytics, and automation to empower our clients with faster, smarter, and more cost-effective decision-making.
What This Means for 2025
This funding will allow us to:
✅ Accelerate the development of the Aurora Suite, making it even more robust and user-friendly.
✅ Strengthen our team by expanding expertise in AI, data science, and clinical trial strategy.
✅ Scale our impact, ensuring that more companies can benefit from our innovative solutions.
A Step Forward in Our Mission
This award is not just about funding—it’s a reflection of our growing momentum. With each step forward, we are solidifying Aurora Analytica’s position as a leader in clinical trial optimization. Our commitment to innovation, data-driven decision-making, and improving patient outcomes remains stronger than ever.
Thank You, Innovation Norway!
We are incredibly grateful for Innovation Norway’s continued belief in our work. This milestone brings us one step closer to reshaping the future of clinical trials—delivering smarter strategies, reducing costs, and ultimately bringing life-changing treatments to patients faster.
Stay tuned for more updates as we embark on this exciting phase of growth.
